Literature DB >> 7645263

Functional analysis of EA-D of Epstein-Barr virus.

L W Chen1, L S Lin, Y S Chang, S T Liu.   

Abstract

Different mutations were generated in the diffused-form early antigen (EA-D) of Epstein-Barr virus (EBV) for study of the effects of these mutations in DNA binding, stimulating the activity of EBV-specific DNA polymerase (EBV-DP), and binding to monoclonal antibody R3. Results revealed that the N-terminal 303 amino acids were essential for DNA binding and were sufficient for the enhancement of the activity of EBV-specific DNA polymerase. Deletion study also showed that the region recognized by the R3 monoclonal antibody was located between aa 315 and aa 377. Our results failed to demonstrate the binding between EA-D and EBV-DP, using the proteins synthesized in vitro, suggesting that direct contact between the two proteins is not required for the EBV-DP activity in vitro. We have generated fusion between EA-D and DNA-binding domain of yeast GAL4 protein; however, this fusion protein was not able to transactivate the promoter containing UAS sequence in P3HR1 cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7645263     DOI: 10.1006/viro.1995.1443

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.

Authors:  L K Chang; S T Liu
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

2.  Tetrameric ring formation of Epstein-Barr virus polymerase processivity factor is crucial for viral replication.

Authors:  Sanae Nakayama; Takayuki Murata; Yoshihiro Yasui; Kazutaka Murayama; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  The Epstein-Barr virus protein BMRF1 activates gastrin transcription.

Authors:  Elizabeth A Holley-Guthrie; William T Seaman; Prasanna Bhende; Juanita L Merchant; Shannon C Kenney
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein.

Authors:  Sanae Nakayama; Takayuki Murata; Kazutaka Murayama; Yoshihiro Yasui; Yoshitaka Sato; Ayumi Kudoh; Satoko Iwahori; Hiroki Isomura; Teru Kanda; Tatsuya Tsurumi
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157

5.  Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.

Authors:  Q Zhang; Y Hong; D Dorsky; E Holley-Guthrie; S Zalani; N A Elshiekh; A Kiehl; T Le; S Kenney
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency.

Authors:  A L Francis; L Gradoville; G Miller
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Regulation of Epstein-Barr virus promoters in oral epithelial cells and lymphocytes.

Authors:  L A Lagenaur; J M Palefsky
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  The SWI/SNF Chromatin Regulator BRG1 Modulates the Transcriptional Regulatory Activity of the Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1.

Authors:  Mei-Tzu Su; Ya-Ting Wang; Yen-Ju Chen; Su-Fang Lin; Ching-Hwa Tsai; Mei-Ru Chen
Journal:  J Virol       Date:  2017-04-13       Impact factor: 5.103

9.  Characterization of human herpesvirus 8 ORF59 protein (PF-8) and mapping of the processivity and viral DNA polymerase-interacting domains.

Authors:  S R Chan; B Chandran
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.

Authors:  V L Zacny; E Gershburg; M G Davis; K K Biron; J S Pagano
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.